Emerging Strategies for the Prevention of Immune Toxicities Associated with T cell-Engaging Cancer Therapies.
Blood Cancer Discov
; 5(2): 90-94, 2024 Mar 01.
Article
em En
| MEDLINE
| ID: mdl-38175152
ABSTRACT
SUMMARY:
Immune-related toxicities including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) are common side effects of bispecific antibody and chimeric antigen receptor (CAR) T-cell therapies of hematologic malignancies. As anti-inflammatory therapy (the standard of care) is variably effective in mitigating these toxicities after onset, here we discuss emerging evidence for shifting the strategy from mitigation to prevention.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Anticorpos Biespecíficos
/
Neoplasias Hematológicas
/
Neoplasias
Tipo de estudo:
Risk_factors_studies
Limite:
Humans
Idioma:
En
Ano de publicação:
2024
Tipo de documento:
Article